The Directory of Pharma Companies and News

Ipsen Ltd

Ipsen Ltd is a global specialty-driven biotechnological group with total sales exceeding �1.2 billion in 2014. Ipsen sells more than 20 drugs in more than 115 countries, with a direct commercial presence in 30 countries. Ipsen�s ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and urologyoncology. Ipsen�s commitment to oncology is exemplified through its growing portfolio of key therapies improving the care of patients suffering from prostate cancer, bladder cancer or neuroendocrine tumors. Ipsen also has a significant presence in primary care. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins, located in the heart of the leading biotechnological and life sciences hubs (Les Ulis, France; Slough/Oxford, UK; Cambridge, US). In 2014, R&D expenditure totaled close to �187 million, representing about 15% of Group sales. The Group has more than 4,500 employees worldwide. Ipsen�s shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the �Service de R�glement Diff�r�� (�SRD�). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit

Ipsen Ltd News

2016-09-27Ipsen announces data presentations of cabozantinib (Cabometyx™), lanreotide (Somatuline® Autogel®) and telotristat ethyl... (PDF)
2016-09-14European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinom... (PDF)
2016-08-01Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for injection for the treatment of Lower Limb Spasticity i... (PDF)
2016-07-28Ipsen’s First Half 2016 Results (PDF)
2016-07-28Supplemental Application Filed for Somatuline® in Japan for Additional Indication of Neuroendocrine Tumors (PDF)
2016-07-22Ipsen and its partner Exelixis receive positive CHMP opinion for Cabometyx™ (cabozantinib) for the treatment of advanced... (PDF)
2016-07-18Ipsen announces the acceptance by the European Medicines Agency of the marketing authorization application for telotrist... (PDF)
2016-07-11David Meek appointed as Chief Executive Officer of Ipsen (PDF)
2016-06-09Ipsen successfully issues inaugural €300 million 7-year Notes (PDF)
2016-06-06Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CAB... (PDF)
2016-06-06The Ipsen Group launches an employee shareholding plan (PDF)
2016-06-05Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX™ (cabozantinib) tablets demonstrating signifi... (PDF)
2016-06-01Eugenia Litz is appointed as Vice President Investor Relations of Ipsen (PDF)
2016-05-31Ipsen’s partner, Lexicon, announced FDA Priority Review of new drug application for telotristat etiprate for the treatme... (PDF)
2016-05-23Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib sign... (PDF)
2016-05-17Ipsen partners with IMCB to advance understanding and research of botulinum neurotoxin biology (PDF)
2016-05-03Oncodesign and Ipsen enter into a strategic partnership in oncology and Oncodesign joins Ipsen’s Paris-Saclay Campus (PDF)
2016-04-28Ipsen’s first quarter 2016 sales up 4.7% (PDF)
2016-04-26Probi and Ipsen sign extensive Primary Care distribution agreement for probiotic LP299V®, Lactobacillus plantarum 299v (PDF)
2016-04-26Ipsen is pleased to announce that its partner Exelixis obtained FDA Approval of CABOMETYX™ (cabozantinib) tablets for pa... (PDF)
2016-04-05Dassault Systèmes and Ipsen sign collaborative agreement to develop innovative programs to support Ipsen’s drug discover... (PDF)
2016-03-31The Ipsen Group publishes its 2015 Registration Document (PDF)
2016-03-08Ipsen and PeptiMimesis announce a research partnership in oncology (PDF)
2016-03-01Exelixis and Ipsen enter into exclusive licensing agreement to commercialize and develop novel cancer therapy Cabozantin... (PDF)
2016-03-01Ipsen’s 2015 results and 2016 financial objectives (PDF)
2016-02-17Ipsen enters into a licensing agreement with 3B Pharmaceuticals to develop novel radiopharmaceuticals in oncology (PDF)
2016-02-16Changes to Ipsen corporate governance (PDF)
2016-01-26Ipsen announces publication in Pediatrics of the results of the phase III randomized study showing the efficacy and safe... (PDF)
2016-01-06Ipsen and Galderma expand current distribution agreement for Dysport® in aesthetic indications to some key Asia-Pacific ... (PDF)
2015-12-17Ipsen announces its corporate agenda for 2016 (PDF)
2015-12-01Ipsen’s partner Lexicon announced that Telotristat Etiprate had achieved positive top-line results in second phase 3 cli... (PDF)
2015-11-19Ipsen and Interprotein enter into a research collaboration for novel peptides in endocrinology (PDF)
2015-10-29Ipsen: sales in the 3rd quarter and first nine months of 2015 (PDF)
2015-10-28Telesta Therapeutics and Ipsen announce exclusive license agreement for MCNA for the treatment of non-muscle invasive bl... (PDF)
2015-10-26Ipsen and EpiVax collaborate to produce next generation botulinum toxins (PDF)
2015-10-22Ipsen presents additional results from a Phase III clinical trial of the investigational use of Dysport® in children wit... (PDF)
2015-10-19Ipsen’s partner Lexicon announced at the 2015 Neuroendocrine Tumor Society Annual Symposium (Austin, Texas) that telotri... (PDF)
2015-10-01Stéphane Bessette is appointed Executive Vice President, Human Resources of Ipsen (PDF)
2015-10-01Ipsen announces release of an additional batch of Increlex® in the U.S. (PDF)
2015-09-29Ipsen’s partner Lexicon presents phase III TELESTAR study data at ECC 2015 (Vienna, Austria) showing that telotristat et... (PDF)
2015-08-31Ipsen announces publication in The Lancet Neurology of the results of the phase III randomized study (NCT01313299) showi... (PDF)
2015-08-03Ipsen’s partner, Lexicon Pharmaceuticals, announces positive results from TELESTAR phase 3 study showing that telotrista... (PDF)
2015-07-31Ipsen: 2015 half-year results (PDF)
2015-07-31Ipsen: 2015 half-year results and 2015 objectives (PDF)
2015-07-16Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in... (PDF)
2015-07-02Ipsen provides an update on 2020 strategy and outlook at Investor Day (PDF)
2015-06-03Ipsen initiates a share buyback program Shares will be cancelled to compensate dilution resulting from its free share pl... (PDF)
2015-06-02Ipsen confirms its eligibility for PEA-PME (PDF)
2015-05-29Combined Shareholders’ Meeting of IPSEN S.A. held on 27 May 2015 (PDF)
2015-05-19Ipsen strengthens its presence in the oncology field with the acquisition of OctreoPharm Sciences, a company developing ... (PDF)
2015-04-29Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year (PDF)
2015-04-16Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer (PDF)
2015-04-08Ipsen and Hannover Medical School start joint research in recombinant botulinum neurotoxins for targeted secretion inhib... (PDF)
2015-04-01Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub ... (PDF)
2015-04-01Ipsen expands ties to Harvard University with signing of a new Research Alliance Agreement (PDF)
2015-03-31The Ipsen Group publishes its 2014 Registration document (PDF)
2015-03-04Precisions concerning the resupply of Increlex® in the U.S. (PDF)
2015-03-03Ipsen’s 2014 results and 2015 financial objectives (PDF)
2015-03-02Dominique Laymand is appointed as Ipsen’s Senior Vice President, Chief Ethics and Compliance Officer (PDF)
2015-03-02Ipsen Announces Third Resupply of Increlex® (mecasermin [rDNA origin] Injection) in the U.S. in 2015 (PDF)
2015-02-24Ipsen enters into option agreement to acquire Canbex Therapeutics (PDF)
2015-02-03Ipsen: sales in the fourth quarter and full year 2014 (PDF)
2015-01-26Ipsen announces topline results of two double-blind phase III studies of Dysport® in lower limb spasticity in children a... (PDF)
2015-01-07Ipsen announces its corporate agenda for 2015 (PDF)
2014-12-16François Garnier appointed Executive Vice President, General Counsel of Ipsen (PDF)
2014-12-16Ipsen’s Somatuline® Depot® is the first therapy approved by the FDA in the United States for the treatment of patients w... (PDF)
Brought to you by - Latest Jobs in Pharma
Brought to you by - Latest Jobs in Pharma.